Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
27.95
-1.68 (-5.65%)
Mar 31, 2025, 9:55 AM EDT - Market open
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Kymera Therapeutics stock have an average target of 56.69, with a low estimate of 36 and a high estimate of 74. The average target predicts an increase of 102.86% from the current stock price of 27.95.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 5 | 5 | 4 | 5 |
| Buy | 5 | 6 | 7 | 7 | 5 | 5 |
| Hold | 4 | 4 | 4 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 14 | 16 | 15 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $52 | Strong Buy | Initiates | $52 | +86.08% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $54 → $60 | Strong Buy | Maintains | $54 → $60 | +114.71% | Feb 28, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $60 | Buy | Reiterates | $60 | +114.71% | Jan 21, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $60 | Buy | Maintains | $60 | +114.71% | Dec 27, 2024 |
| BTIG | BTIG | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +114.71% | Dec 10, 2024 |
Financial Forecast
Revenue This Year
68.22M
from 47.07M
Increased by 44.93%
Revenue Next Year
66.74M
from 68.22M
Decreased by -2.18%
EPS This Year
-3.71
from -2.98
EPS Next Year
-4.14
from -3.71
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 171.2M | 171.2M | 245.7M | ||
| Avg | 68.2M | 66.7M | 90.7M | ||
| Low | 13.3M | n/a | -37.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 263.6% | 150.9% | 268.2% | ||
| Avg | 44.9% | -2.2% | 35.9% | ||
| Low | -71.7% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.54 | -3.27 | -2.86 | ||
| Avg | -3.71 | -4.14 | -4.09 | ||
| Low | -4.63 | -5.87 | -7.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.